FAR2 (Fatty Acyl-CoA Reductase 2) is an enzyme involved in fatty acid metabolism, specifically in the biosynthesis of ether lipids and wax esters. It catalyzes the reduction of fatty acyl-CoA to fatty alcohols, a critical step in generating lipid components essential for cellular membrane structure and signaling. FAR2 is primarily expressed in tissues with high lipid metabolism, such as the liver, brain, and skin, and localizes to the endoplasmic reticulum.
Antibodies targeting FAR2 are valuable tools for studying its expression, localization, and function in physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate FAR2's role in lipid homeostasis, cell differentiation, and disease mechanisms. Research has linked FAR2 dysregulation to metabolic disorders, neurodegenerative conditions, and cancer progression, highlighting its potential as a therapeutic target or biomarker.
Commercial FAR2 antibodies are typically raised against specific epitopes, such as human FAR2's N-terminal or catalytic domains, and validated for species cross-reactivity (e.g., human, mouse, rat). Recent studies also explore FAR2's interaction with lipid droplets and its response to nutritional stimuli, underscoring its importance in energy storage and metabolic adaptation. Ongoing research aims to clarify FAR2's tissue-specific functions and its interplay with other lipid-metabolizing enzymes.